Cancer Genetics and Epigenetics 2024, Vol.12, No.4, 182-193 http://medscipublisher.com/index.php/cge 189 being investigated for their potential to achieve efficient and targeted siRNA delivery with minimal systemic toxicity (Subhan et al., 2021). 6 Clinical Trials and Therapeutic Outcomes 6.1 Overview of clinical trials RNA interference (RNAi) has shown significant promise in the treatment of various cancers, including cervical cancer. Several clinical trials have been initiated to explore the efficacy and safety of RNAi-based therapies. For instance, a first-in-human trial of ALN-VSP, an LNP formulation of siRNAs targeting VEGF and kinesin spindle protein (KSP), demonstrated the presence of the drug in tumor biopsies and siRNA-mediated mRNA cleavage in the liver, indicating successful delivery and target downregulation (Tabernero et al., 2013). Additionally, by 2018, around 20 clinical trials focusing on cancer and diabetes had progressed to Phase II, testing the safety and efficacy of siRNA (Alzhrani et al., 2020). The resurgence in RNAi clinical trials since 2012 has led to more than 20 RNAi-based therapeutics currently being tested, with several in Phase III trials (Bobbin and Rossi, 2016). 6.2 Efficacy and safety profiles The clinical outcomes of RNAi-based therapies have been promising, with several studies reporting significant antitumor activity and manageable safety profiles. For example, the ALN-VSP trial showed complete regression of liver metastases in endometrial cancer and was well tolerated with biweekly intravenous administration (Tabernero et al., 2013). Another study highlighted the potential of RNAi to silence genes involved in disease, showing that systemic administration of siRNA could produce specific gene inhibition in humans without producing an interferon response (Davis et al., 2010). Despite initial challenges, advances in delivery systems and improved chemistry have enhanced the efficacy and safety of RNAi therapeutics, making them viable options for cancer treatment (Bobbin and Rossi, 2016). 6.3 Comparative analysis with other therapies When compared to existing cervical cancer therapies, RNAi-based treatments offer several advantages. Traditional therapies, such as chemotherapy and radiotherapy, often come with significant side effects and may not specifically target cancer cells. RNAi, on the other hand, provides a mechanism for specific gene silencing, potentially reducing off-target effects and improving therapeutic outcomes (Takeshita and Ochiya, 2006; Phalon et al., 2010). Moreover, RNAi can target multiple genes simultaneously, increasing the number of druggable targets and offering a more comprehensive approach to cancer treatment (Tabernero et al., 2013). However, challenges such as effective in vivo delivery and overcoming nonspecific immune responses remain, necessitating further research and development (Pai et al., 2006). 7 Challenges and Future Directions 7.1 Overcoming delivery barriers The delivery of RNA interference (RNAi) therapeutics, particularly small interfering RNAs (siRNAs), faces significant challenges due to their instability and difficulty in reaching target cells. Technological advancements are crucial to improve the delivery systems for RNAi. Nanoparticle-based delivery systems, including lipid-based nanoparticles and polymer-based carriers, have shown promise in enhancing the stability and targeting efficiency of siRNAs. These systems can protect siRNAs from degradation, facilitate their transport across cellular barriers, and ensure their release at the target site (Miele et al., 2012; Chen et al., 2018; Chen et al., 2021). Additionally, folate receptor-mediated delivery systems have been developed to enhance the uptake of siRNAs by tumor cells, leveraging the overexpression of folate receptors in many cancers (Gangopadhyay et al., 2021). 7.2 Addressing off-target effects One of the major concerns with RNAi therapy is the potential for off-target effects, which can lead to unintended gene silencing and immune responses. Strategies to minimize these effects include the design of highly specific siRNA sequences and the use of advanced bioinformatics tools to predict and avoid off-target interactions (Pai et al., 2006; Miele et al., 2012; Deng et al., 2014). Moreover, chemical modifications of siRNAs, such as 2'-O-methyl and phosphorothioate modifications, can enhance their specificity and reduce immunogenicity (Takeshita and Ochiya, 2006; Singh et al., 2018). The development of delivery systems that can target siRNAs
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==